These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

246 related items for PubMed ID: 21841207

  • 21. Efficacy and safety of vernakalant in patients with atrial flutter: a randomized, double-blind, placebo-controlled trial.
    Camm AJ, Toft E, Torp-Pedersen C, Vijayaraman P, Juul-Moller S, Ip J, Beatch GN, Dickinson G, Wyse DG, Scene 2 Investigators.
    Europace; 2012 Jun; 14(6):804-9. PubMed ID: 22291438
    [Abstract] [Full Text] [Related]

  • 22. Vernakalant hydrochloride for the treatment of atrial fibrillation.
    Kozlowski D, Budrejko S, Lip GY, Mikhailidis DP, Rysz J, Raczak G, Banach M.
    Expert Opin Investig Drugs; 2009 Dec; 18(12):1929-37. PubMed ID: 19938903
    [Abstract] [Full Text] [Related]

  • 23. n-3 polyunsaturated fatty acids for the prevention of arrhythmia recurrence after electrical cardioversion of chronic persistent atrial fibrillation: a randomized, double-blind, multicentre study.
    Bianconi L, Calò L, Mennuni M, Santini L, Morosetti P, Azzolini P, Barbato G, Biscione F, Romano P, Santini M.
    Europace; 2011 Feb; 13(2):174-81. PubMed ID: 21059740
    [Abstract] [Full Text] [Related]

  • 24. 1:1 atrial flutter after vernakalant administration for atrial fibrillation cardioversion.
    de Riva-Silva M, Montero-Cabezas JM, Salgado-Aranda R, López-Gil M, Fontenla-Cerezuela A, Arribas-Ynsaurriaga F.
    Rev Esp Cardiol (Engl Ed); 2012 Nov; 65(11):1062-4. PubMed ID: 22727797
    [No Abstract] [Full Text] [Related]

  • 25. Oral amiodarone increases the efficacy of direct-current cardioversion in restoration of sinus rhythm in patients with chronic atrial fibrillation.
    Capucci A, Villani GQ, Aschieri D, Rosi A, Piepoli MF.
    Eur Heart J; 2000 Jan; 21(1):66-73. PubMed ID: 10610746
    [Abstract] [Full Text] [Related]

  • 26. A comparison between oral antiarrhythmic drugs in the prevention of atrial fibrillation after cardiac surgery: the pilot study of prevention of postoperative atrial fibrillation (SPPAF), a randomized, placebo-controlled trial.
    Auer J, Weber T, Berent R, Puschmann R, Hartl P, Ng CK, Schwarz C, Lehner E, Strasser U, Lassnig E, Lamm G, Eber B, Study of Prevention of Postoperative Atrial Fibrillation.
    Am Heart J; 2004 Apr; 147(4):636-43. PubMed ID: 15077078
    [Abstract] [Full Text] [Related]

  • 27. Chemical cardioversion of recent-onset atrial fibrillation in the emergency department using vernakalant hydrochloride achieves safe and rapid restoration of sinus rhythm and facilitates same day discharge.
    Stoneman P, Gilligan P, Mahon P, Sheahan R.
    Ir J Med Sci; 2017 Nov; 186(4):903-908. PubMed ID: 28168639
    [Abstract] [Full Text] [Related]

  • 28. Systematic Review and Meta-analysis Appraising Efficacy and Safety of Vernakalant for Cardioversion of Recent-Onset Atrial Fibrillation.
    Ma W, Guo X, Wang Q, Sun G, Wang J.
    J Cardiovasc Pharmacol; 2020 Jul; 76(1):32-41. PubMed ID: 32251022
    [Abstract] [Full Text] [Related]

  • 29. Vernakalant, a mixed sodium and potassium ion channel antagonist that blocks K(v)1.5 channels, for the potential treatment of atrial fibrillation.
    Billman GE.
    Curr Opin Investig Drugs; 2010 Sep; 11(9):1048-58. PubMed ID: 20730700
    [Abstract] [Full Text] [Related]

  • 30. Population pharmacokinetics of vernakalant hydrochloride injection (RSD1235) in patients with atrial fibrillation or atrial flutter.
    Mao ZL, Townsend RW, Gao Y, Wheeler JJ, Kastrissios H, Keirns J.
    J Clin Pharmacol; 2012 Jul; 52(7):1042-53. PubMed ID: 21659624
    [Abstract] [Full Text] [Related]

  • 31. [Vernakalant--a new drug for pharmacological conversion of atrial fibrillation].
    Hinneburg I.
    Med Monatsschr Pharm; 2011 May; 34(5):154-8. PubMed ID: 21644373
    [Abstract] [Full Text] [Related]

  • 32. Celivarone for maintenance of sinus rhythm and conversion of atrial fibrillation/flutter.
    Khitri AR, Aliot EM, Capucci A, Connolly SJ, Crijns H, Hohnloser SH, Kulakowski P, Roy D, Radzik D, Kowey PR.
    J Cardiovasc Electrophysiol; 2012 May; 23(5):462-72. PubMed ID: 22171925
    [Abstract] [Full Text] [Related]

  • 33. [Cibenzoline versus propafenone by the oral route for preventing recurrence of atrial arrhythmia: multicenter, randomized, double-blind study].
    Lardoux H, Maison Blanche P, Marchand X, Canler A, Rouesnel P, Bleinc D, Péraudeau P, Scheck F.
    Ann Cardiol Angeiol (Paris); 1996 Oct; 45(8):469-79. PubMed ID: 8952741
    [Abstract] [Full Text] [Related]

  • 34. Vernakalant--a promising therapy for conversion of recent-onset atrial fibrillation.
    Naccarelli GV, Wolbrette DL, Samii S, Banchs JE, Penny-Peterson E, Stevenson R, Gonzalez MD.
    Expert Opin Investig Drugs; 2008 May; 17(5):805-10. PubMed ID: 18447605
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. A randomized, controlled trial of RSD1235, a novel anti-arrhythmic agent, in the treatment of recent onset atrial fibrillation.
    Roy D, Rowe BH, Stiell IG, Coutu B, Ip JH, Phaneuf D, Lee J, Vidaillet H, Dickinson G, Grant S, Ezrin AM, Beatch GN, CRAFT Investigators.
    J Am Coll Cardiol; 2004 Dec 21; 44(12):2355-61. PubMed ID: 15607398
    [Abstract] [Full Text] [Related]

  • 38. Safety and efficacy of pharmacological cardioversion of atrial fibrillation using intravenous vernakalant, a new antiarrhythmic drug with atrial selectivity.
    Blomström-Lundqvist C, Blomström P.
    Expert Opin Drug Saf; 2012 Jul 21; 11(4):671-9. PubMed ID: 22632377
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.